Structure Therapeutics Inc.

Structure Therapeutics Inc. announced that its management will participate in two upcoming healthcare conferences in June. The company will attend the 2026 Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. Both events will include fireside chats and one-on-one meetings, with webcasts available on the company's website.

Structure Therapeutics Inc. reported a net loss of $(76.0) million for Q1 2026, a significant increase from $(46.8) million in Q1 2025, driven by higher research and development and general and administrative expenses. Despite the increased loss, the company generated $15.2 million in net cash from operating activities, a notable improvement from a net cash outflow in the prior year. As of March 31, 2026, the company held $1.46 billion in cash, cash equivalents, and short-term investments, which it expects to fund operations for at least 12 months. The company also amended its ATM Sales Agreement in May 2026, increasing the aggregate offering price to $400.0 million, with $341.5 million remaining available.

Structure Therapeutics Inc. reported its first quarter 2026 financial results and provided a comprehensive business update. The company announced positive Phase 2 ACCESS II study results for aleniglipron, an oral GLP-1RA, showing up to 16.3% body weight loss at 44 weeks, and confirmed positive end-of-Phase 2 FDA feedback, with Phase 3 initiation on track for Q3 2026. Additionally, the company amended its ATM sales agreement, increasing the aggregate offering price of American Depositary Shares by $150 million to $400 million, and reported a strong cash position of $1.5 billion, providing a cash runway through the end of 2028.

Structure Therapeutics Inc. announced multiple presentations at the American Diabetes Association (ADA) 86th Scientific Sessions in June 2026. Key presentations include an oral presentation on the ACCESS Phase 2b clinical trial of aleniglipron, an oral small molecule GLP-1RA, demonstrating meaningful weight reductions in people with obesity and overweight. Additional presentations will cover safety, tolerability, and efficacy of aleniglipron in the ACCESS II trial, exploring lower starting doses for improved GI tolerability, and combination treatment data with ACCG-2671 showing additional weight loss.

Structure Therapeutics Inc. announced the appointment of Matthew Lang as its Chief Operating Officer and General Counsel, effective April 15, 2026. Mr. Lang brings extensive experience from previous leadership roles at biopharmaceutical companies such as Metsera, Lyell Immunopharma, Myovant Sciences, and Gilead Sciences. His appointment is expected to strengthen the company's operational and legal leadership.